A new study has recently looked at breast cancer in other ways. The recent study investigated a potentially better breast cancer treatment and revealed that shorter periods of radiation therapy might lead to a lower toxicity exposure complete with, thankfully, also a better quality of life after the treatment.
The recent study makes use of new technologies available at the moment. Dr. Simona Shaitelman, an assistant professor at Radiation Oncology said that the studies were carried out using now-antiquated technologies. Ever since then, along with the advancements in technology, random studies conducted in Canada and the United Kingdom have revealed equal rates of recurrence for both the study groups. The studies also showed equal survival. However, the radiation oncology community has yet to adopt the new practices.
On top of this, Shaitelman, who is also the lead author of the study said that the basic idea of the study is that women who are 40 years old or over who suffer from breast cancer in the early stage, higher and shorter doses of radiation should be the standard treatment. Longer-course treatment has been for a very long time the standard, and this should be changed.
Shaitelman said that the question is, with newer technology, and knowing the fact recurrence and survival outcomes are the same, is there something a lot better that could be offered to the patients? She added that it was crucial for them to analyze how they were offering therapy and if said therapy was actually improving the quality of the patient’s life, both in the short period after the treatment and during the treatment.
Shaitelman also said that the patients who received the shorter period claimed fewer troubles in caring for the needs of their families. For the women who are undergoing breast cancer radiation this is a major priority. Most of these women are working mothers, working outside and inside their households, and are dealing with numerous priorities. She said that it is important that they address this issue.
Jennifer Bellon and Shyam Tangturi, two Harvard-affiliated doctors have said that with lower costs, reduced mortality and comparable tumor control, hypofractionation should be taken into account for the majority of people who suffer from breast cancer in the early stages.
The new treatment investigating a potentially better breast cancer treatment was published in the JAMA Oncology medical journal on August 6.
Image Source: lafitness.files.wordpress.com